U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07324616) titled 'A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment' on Dec. 23, 2025.
Brief Summary: The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment (HI)
Intervention:
DRUG: EDG-7500
Single dose of EDG-7500
Recruitment Status: NOT_...